Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Diego, California
Dates
study started
completion around
Principal Investigator
by Adam Burgoyne, MD, PhD
Headshot of Adam Burgoyne
Adam Burgoyne

Description

Summary

The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma. After this procedure, participants will be treated with tremelimumab and durvalumab every 4 weeks (STRIDE regimen).

Official Title

A Phase Ib Study of Cryoablation and Pressure-enabled Hepatic Arterial Infusion of Class C Toll-like Receptor 9 Agonist SD-101 in Combination with Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Details

Keywords

Hepatocellular Carcinoma, Carcinoma, Durvalumab, Tremelimumab, Cryotherapy

Eligibility

Location

  • University of California, San Diego accepting new patients
    San Diego California 92093 United States

Lead Scientist at UCSD

  • Adam Burgoyne, MD, PhD
    Associate Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 35 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT06710223
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 20 study participants
Last Updated